Advertisement
Singapore markets close in 3 hours 26 minutes
  • Straits Times Index

    3,145.30
    -38.31 (-1.20%)
     
  • Nikkei

    38,518.89
    -713.91 (-1.82%)
     
  • Hang Seng

    16,335.70
    -264.76 (-1.59%)
     
  • FTSE 100

    7,965.53
    -30.05 (-0.38%)
     
  • Bitcoin USD

    62,716.22
    -2,503.52 (-3.84%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     
  • Dow

    37,735.11
    -248.13 (-0.65%)
     
  • Nasdaq

    15,885.02
    -290.08 (-1.79%)
     
  • Gold

    2,403.70
    +20.70 (+0.87%)
     
  • Crude Oil

    85.97
    +0.56 (+0.66%)
     
  • 10-Yr Bond

    4.6280
    +0.1290 (+2.87%)
     
  • FTSE Bursa Malaysia

    1,536.82
    -5.71 (-0.37%)
     
  • Jakarta Composite Index

    7,144.55
    -142.33 (-1.95%)
     
  • PSE Index

    6,437.00
    -125.43 (-1.91%)
     

Why Esperion Therapeutics Plummeted Nearly 22% Today

Why Esperion Therapeutics Plummeted Nearly 22% Today

Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. In Q1 Esperion earned $8 million, over four times the $1.8 million of Q1 2020, fueled by $6.4 million in product revenue (royalty revenue came in at roughly $600,000).